Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon


TEL: +886-2-28712121 Ext.2148
現職: 李偉平大夫
  • 慢性發炎的腸胃上皮細胞端粒(Telomere)之長度變化,在經過治療,慢性發炎消除後,端粒長度之改變, 並研究造成此種改變之機轉。
  • 端粒?(Telomerase)是延長端粒之酵素,我們研究腸胃腫瘤細胞Telomerase 活化之因素。
  • B 型肝炎病毒 X 蛋白之亞型 (Isoform) 與肝癌發生之關係。
  • 低劑量之節拍式化療對循環血管內皮細胞 (Circulating endothelial cell)之影響。
《代表著作 》
  1.   Wang YK, Wang YW, Lu CL, Huang YH, Hou MC, Chang YL, Lee WP*, Lan KH. Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol. Scientific Report, 2022 Jun 15;12(1):9942
  2.   Lee WP*. Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors. J Chin Med Assoc, 2022 Sep 1;85(9):915-921.
  3.   Wang YW, Lee WP(co-first author), Huang YH, Hou MC, Lan KH. Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):984-995.
  4.   Wang YK, Lee WP (co-first author), Wang YW, Huang YH, Hou MC, Chang YL, Lan KH. Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir. J Chin Med Assoc. 2020, 83: 1071-1078
  5.   Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH. Antiviral effect of saikosaponin B2 in combination with daclatasvir on NS5A resistance-associated substitutions of hepatitis C virus. J Chin Med Assoc. 2019;82:368-374.
  6.   Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH. Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus. Am J Chin Med 2018;46:835-852.
  7.   Lan KH, Lee WP, Wang YS, Liao SX, Lan KH. Helicobacter pylori CagA protein activates Akt and attenuates chemotherapeutics-induced apoptosis in gastric cancer cells. Oncotarget. 2017;8:113460-113471. 
  8.   *Lee WP, Lan KH, Li CP, Chao Y, Hou MC, Lin HC, Lee SD. The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine. BBA-Mole. Basis Disease. 2017;1863(4):917-928.